Lincoln A Edwards

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi request reprint Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, BC, Canada
    Oncogene 24:3596-605. 2005
  2. doi request reprint Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 7:59-70. 2008
  3. ncbi request reprint Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 5:645-54. 2006
  4. ncbi request reprint Integrin-linked kinase (ILK) in combination molecular targeting
    Lincoln A Edwards
    Advanced Therapeutics, BC Cancer Agency and Research Centre, Department of Pathology and Laboratory Medicine, The University of British Columbia
    Cancer Treat Res 119:59-75. 2004
  5. ncbi request reprint Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs
    Gigi N C Chiu
    Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
    Mol Cancer Ther 6:844-55. 2007

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, BC, Canada
    Oncogene 24:3596-605. 2005
    ..Our initial results indicate that therapeutic strategies targeting ILK may be beneficial in the treatment of glioblastomas...
  2. doi request reprint Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK)
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 7:59-70. 2008
    ..The therapeutic effects of a selected ILK inhibitor (QLT0267) should be determined in the clinic in cancers that exhibit dysregulated ILK, such as PTEN-null glioblastomas...
  3. ncbi request reprint Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells
    Lincoln A Edwards
    Department of Advanced Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada
    Mol Cancer Ther 5:645-54. 2006
    ..Combinations targeting ILK and components of the Ras/MAPK pathway result in synergy and could potentially be more effective against glioblastoma cancer than monotherapy...
  4. ncbi request reprint Integrin-linked kinase (ILK) in combination molecular targeting
    Lincoln A Edwards
    Advanced Therapeutics, BC Cancer Agency and Research Centre, Department of Pathology and Laboratory Medicine, The University of British Columbia
    Cancer Treat Res 119:59-75. 2004
  5. ncbi request reprint Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs
    Gigi N C Chiu
    Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore
    Mol Cancer Ther 6:844-55. 2007
    ..The data presented here showed the potential of liposome technology to enhance the therapeutic effect of antibodies via a mechanism that modulates cell survival through clustering of the target/antibody complex...